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Background: Rapid diagnostics tests for malaria (RDT) have become established as a practical solution to the
challenges of parasitological confirmation of malaria before treatment in the public sector. However, little is known
of their impact in private health sector facilities, such as pharmacies and drug shops. This study aimed to assess the
incidence of malaria among unwell patients seeking anti-malarial treatment in two community pharmacies in
Nigeria and measure the impact RDTs have on anti-malarial sales.
Methods: This was a comparison study of two pharmacies located in the suburbs of Gwagwalada, in the
Federal Capital Territory of Nigeria, between May and July 2012. In the intervention arm, patients seeking to
purchase anti-malarials had an RDT performed before treatment while the control pharmacy continued normal
routine practice.
Results: A total of 1,226 participants were enrolled into the study. The incidence of malaria in the intervention arm
(n = 619) was 13.6% and adolescent participants had a statistically significant higher incidence (26.0%) compared to
adults (11.9%) (P = 0.001). A history of fever in the last 48 hours was associated with a statistically significant higher
incidence of malaria (28.3%) (P < 0.001). Having a RDT test reduced the chance of purchasing an anti-malarial by
42% (95% CI: 38%-46%) compared to not having a test. 51.6% (276) of the study participants with a RDT negative
result still purchased anti-malarials, especially if anti-malarials had been recommended by a health professional
(58.9%) compared to self-referral (44.2%) (P = 0.001). Patients with RDT negative results were also more likely to
purchase an anti-malarial if there was a reported malaria positive laboratory test prior to presentation (66.2%;
P = 0.007), a history of fever in the last 48 hours (60.5%; P = 0.027), and primary school education or less (69.4%;
P = 0.009). After adjusting for age group and gender differences, having at least a secondary school education
reduced the chance of buying an anti-malarial (OR 0.504 (95% CI: 0.256-0.993)) compared to having primary
education or lower.
Conclusion: The study highlights the enormous potential for improving appropriate prescription of anti-malarials in
pharmacies and preventing unnecessary use of artemisinin combination therapy (ACT).
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Malaria has been a global public health problem for more
than a century, claiming the lives of millions each year
and reducing the quality of life of many others, especially
in sub-Saharan Africa (SSA), where it still remains a se-
rious concern [1]. The declining morbidity and mortality
from malaria [2-10] raises concerns about the rationale
for presumptive management of malaria. Despite its ques-
tionable economic value, presumptive management of
malaria is still common in SSA. Many patients are in-
appropriately treated with anti-malarials with no improve-
ment, exposure to unnecessary potential side effects and
missed opportunities to treat the real cause of fever
[11,12]. However, prompt parasitological confirmation of
malaria before treatment is unrealistic in many settings
because expert laboratory diagnostic services are scarce or
unavailable. The provision of cheap and accurate rapid
point of care tests, that require little skill, is therefore ap-
pealing. In 2011, the World Health Organization (WHO)
expanded their guidelines for the management of uncom-
plicated malaria to specifically include the use of rapid
diagnostic tests (RDTs) for confirmation of malaria before
treatment. Despite this, the use of RDTs remains disap-
pointingly low in public health sector facilities in most
malaria endemic countries [1]. Several studies also show
that RDT use itself may or may not influence a change in
the anti-malarial prescription behaviour of doctors and
other health workers [13-17], but little is known about
RDT use in private health sector facilities - even though
the private sector manages a substantial burden of pre-
sumed malaria in SSA.
The WHO Global Malaria initiative in March 2012
launched the “T3 initiative” to reaffirm the importance of
RDTs in malaria control. This initiative includes: testing
all suspected cases; treating these cases with ACT; and
tracking (monitoring) malaria control programmes. It
aims to help policy makers and donors recognize the im-
portance of scaling up diagnostic testing services (espe-
cially RDT) to match the funding that is already available
for ACT. Studies are needed in private health sector faci-
lities such as pharmacies and drug shops, to build upon
existing evidence that demonstrates the value of RDTs in
malaria control. This study examined the impact of the
introduction of RDTs upon sales of anti-malarials in a
community pharmacy in Gwagwalada, Nigeria, to assess
the incidence of malaria among adolescents and adults
who are unwell and seeking treatment for malaria and to
determine the factors that influenced prescription of anti-
malarials when the malaria RDT was negative.
Methods
Study area
The study was conducted in the suburbs of Gwagwalada
area council, one of six area councils in the FederalCapital Territory of Nigeria, a region reported to be
holo-endemic and perennial for malaria as at the time of
the study [18], but now regarded as meso-endemic in an
unpublished report by the National Malaria Control
Programme (NMCP) [19]. ITN coverage and use are
reportedly low among the population and malaria
accounts for 52% of all inpatient and outpatient visits.
Although the council is covered by a wide variety of
government and privately owned health facilities, the
health worker to patient ratio is still very low (1: 11335)
[20]. Health services at these facilities are not free and
the national anti-malarial treatment policy of Nigeria
does not exclude the sale of anti-malarials without a
doctors’ prescription. Thus, anti-malarials are easily ac-
cessible in the free market, especially in pharmacies. The
national malaria treatment policy, since 2004, includes
the use of artemether-lumefantrine and artemether-amo-
diaquine as first and second line treatment of uncom-
plicated malaria respectively [21]. However, the use of
anti-malarials as monotherapies is still common.
Study design and sampling strategy
The study was a comparison between two pharmacies.
Pharmacies with an average of at least 23 anti-malarial
sales per day in the council area were identified from a list
of eligible pharmacies obtained from the Association of
Community Pharmacists of Nigeria. Pharmacies were
approached to see if they would be willing to participate
in the study. Two community pharmacies were chosen at
random from the list of pharmacies willing to participate.
An initial study was undertaken to determine the com-
mon symptoms of uncomplicated malaria that prompted
patients who were unwell to seek anti-malarial treatment
and to identify the routine prescription practice in both
pharmacies, checking sales records to ensure that baseline
average number of anti-malarial sales per day for both
pharmacies were similar. The initial study also determined
that anti-malarial prescription practice, the availability of
different class of anti-malarials and their cost were similar
in both pharmacies. The intervention pharmacy was then
chosen at random and provided with RDTs: the control
continued with its routine community pharmacy practice.
Participants were eligible if they had symptoms of un-
complicated malaria and were at least ten years of age or
older. Patients were assessed by the study nurse and ex-
cluded from the study if they had symptoms of severe
malaria or were pregnant. Severe malaria was considered
as those with symptoms of malaria and pallor, extreme
weakness and inability to walk, or an inability to tolerate
oral medications. Female adult patients were excluded if
they said they were pregnant, if their last menstrual
period was more than 35 days prior to date of interview
or if they could not remember the date of their last men-
strual period.
Number of pharmacies 
in area council
20
Number of 
pharmacies 
approached                      
12
Two pharmacies 
selected by simple 
random sampling
2 pharmacies 
assigned to 
study arm by a 
toss of a coin
Intervention 
pharmacy
n=619
Control pharmacy  
n= 607
-5 pharmacies 
declined
-3 pharmacies 
excluded
Figure 1 Schematic summary of the number and disposition of
the pharmacies at each stage of selection.
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consent after the study had been explained to them. Par-
ticipants presenting to the intervention pharmacy (either
with a malaria prescription or those seeking to buy anti-
malarials for self-medication) with symptoms of uncom-
plicated malaria were tested using RDTs and shown the
results before drugs were dispensed. The results were also
revealed to the pharmacist. In the case of an RDT negative
result, a decision to suspend anti-malarial treatment was
made following further discussion between the pharmacist
and the patient. The investigator was not involved in the
decision.
An indicative sample size for the study was calculated
assuming that the number of anti-malarial sales per day
in both pharmacies (prior to the intervention) followed a
statistical Poisson distribution with mean 23. Assuming
35 days of observation (during which time 1,610 patients
were expected to participate) and no change in the sales
rate in the control pharmacy, the study had 90% power
to detect a reduction in the average daily number of
anti-malarial sales in the intervention pharmacy from 23
to 19.2 (a 16% reduction).
Rapid tests were conducted using SD BIOLINE Malaria
Antigen Pf (Lot Number: 082112, REF 05FK50, Manufac-
ture date: 18-07-2011, Expiry date: 17-07-2013) by the
study nurse. The kit is included in the WHO/Global Fund
list of quality assured RDTs worldwide [22]. The tests
were carried out in accordance to the instructions in the
manufacturers’ manual. Standard universal precautions
were observed. A positive result was indicated when there
were two colour bands (Pf test line and C test line) within
the result window. The presence of one colour band
(C test line) and no colour band indicated a negative or an
invalid result respectively. The test kit detects HRP-II anti-
gen of Plasmodium falciparum and is reported to be very
stable at temperatures up to 40°C. The sensitivity and spe-
cificity of the kit were reported by the manufacturers as
99.7% and 99.5% respectively. Quality assurance tests were
carried out on the batch of kits used by the Liverpool
School of Tropical Medicine (LSTM) laboratory by testing
25 samples of the RDTs with known positive and negative
malaria samples (confirmed by expert microscopy), repli-
cating field conditions as much as possible. The kits
showed 100% sensitivity and specificity.
Data was collected using Epi-Info version 7 and ana-
lysed using SPSS version 20. The incidence of malaria
was calculated for all participants and for specific sub
groups of particular interest and presented as percen-
tages. The risk factors for malaria were analysed by
multivariate analysis first and then by multivariate linear
regression analysis for statistical significance, adjusting
for age group and gender differences in the population.
The statistical significance level for this study was set at
5%. To determine the impact of RDTs on anti-malarialsales, a cross tabulation of anti-malarial sales between
the two study arms was analysed for risk estimates with
95% Confidence Intervals (95% CI). The risk difference
in sales was calculated by calculating risk ratios and
testing it statistically with Chi-squared tests. To deter-
mine the effect of each variable on anti-malarial sale, a
multivariate analysis comparing anti-malarial sales and
each variable was tested for statistical significance using
Chi-squared tests. All the variables that were statistically
significant were then adjusted for age group and gender
differences by including them into a multivariate linear
regression model through a generalized linear model.
The adjusted odds ratios obtained were interpreted with
a 95% CI.
Ethical approval was granted by the National Health
Research Ethics Committee of Nigeria (NHREC) and the
LSTM Research Ethics Committee.
Results
12 of the 20 registered pharmacies in the area council
were initially approached to participate in the study. Five
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being published, while three pharmacies were excluded
because they did not have sufficient daily anti-malarial
sales to reach the intended sample size for the stipulated
period of the study. Figure 1 shows a summary of the
number and disposition of the pharmacies at each stage of
selection.
The study took place between May and July 2012. A
total of 1226 participants aged 10-78 years (mean age of
30.847, 51.7% females and 88.7% adults) were enrolled
into the study. A large proportion of the study partici-
pants (90.4%) had at least a secondary education while
60.5% of the study population had a below average
monthly income. A detailed summary of the baseline
characteristics of participants in the study is shown in
Table 1.
Incidence and risk factors for malaria
All 619 patients enrolled in the intervention arm were
tested for malaria with RDTs and shown the results beforeTable 1 Baseline characteristics of study participants
Control pharmacy
n = 607
Gender
-Female 328 (54.0%)
-Male 279 (46.0%)
Age (years) 30.12 (10.23)
Age group
-Adolescent 65 (10.7%)
-Adult 542 (89.3%)
Level of education (whole population)
-Primary or less 61 (10%)
-At least secondary 546 (90%)
Level of income
-Less than average income 372 (61.3%)
-Average income or more 235 (38.7%)
Reported last treatment for malaria
-Less than 6 months ago 381 (62.8%)
-More than 6 months ago 226 (37.2%)
Who recommended anti-malarial
-Self 255 (42.0%)
-Health professional 352 (58.0%)
Participants with a doctor’s prescription prior to
purchase of anti-malarial
169 (27.8%)
Reported positive lab test prior to purchase of
anti-malarial
103 (17.0%)
History of fever in the last 48 hours 394 (64.9%)an anti-malarial was dispensed. The incidence of malaria
in the intervention arm was 13.6%. Adolescent par-
ticipants had a statistically significant higher incidence
(26.0%) compared to adults (11.9%) (P = 0.001). Table 2
summarizes the incidence of malaria in the different sub-
study groups analysed. A history of fever in the last
48 hours (26.8% of the test population) was associated
with a statistically significant higher incidence of malaria
(28.3%) (P < 0.001) and 47.1% of adolescents with a history
of fever in the last 48 hours had malaria. Only 22.9%
of participants with a reported recent positive lab test
for malaria at another clinic had malaria on RDT testing.
There was no significant difference between the incidence
of malaria in the sub-population of participants who either
self-recommended malaria treatment (12.5%), or got a rec-
ommendation from a health professional (14.6%).
Table 3 shows the results of a multivariate regression
model that examined risk factors for malaria in the study
population. Adults were much less likely to have malaria
than adolescents (OR 0.514 (95% CI: (0.280-0.946) andIntervention pharmacy Total (n = 1226)
frequency/mean
difference (95% CI)
P value
n = 619
306 (49.4%) 634 (51.7%) 0.107
313 (50.6%) 592 (48.3%)
31.55 (11.46) 1.42 (0.20-2.64) 0.022
73 (11.8%) 138 (11.3%) 0.548
546 (88.2%) 1088 (88.7%)
57 (9.2%) 118 (9.6%) 0.618
562 (90.8%) 1108 (90.4%)
370 (60.5%) 742 (60.5%) 0.588
249 (40.2%) 484 (39.5%)
386 (62.4%) 767 (62.6%) 0.882
233 (37.6%) 459 (37.4%)
303 (48.9%) 558 (45.5%) 0.015
316 (51.1%) 668 (54.5%)
52 (8.4%)) 221 (18.0%) < 0.001
96 (15.5%) 199 (16.2%) 0.488
166 (26.8%) 560 (45.7%) < 0.001
Table 2 Incidence of malaria (using RDTs) in different
sub-populations of patients in the intervention arm
Sub-population Incidence (%) Total number of participants
tested within sub-population
(% distribution within the
total population)
Gender
Female 11.4 306 (49.0%)
Male 15.7 313 (51.0%)
Age group
Adolescent 26.0 73 (11.8%)
Adult 11.9 546 (88.2%)
Level of education (adults)
Primary education
or less
11.8 34 (33.5%)
Secondary education
or more
11.9 512 (66.5%)
Level of income (adults)
Less than average 10.8 297 (59.8%)
Greater than average 13.3 249 (40.2%)
Who recommended
anti-malarial?
Self 12.5 303 (49.0%)
Health professional 14.6 316 (51.0%)
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of fever in the last 48 hours (OR 4.027 (95% CI: 2.482-
6.352)).
Effect of RDT upon anti-malarial sales
An anti-malarial was only dispensed to 360 (59.2%) of
the participants in the intervention pharmacy compared
to 607 (100%) of the participants in the control arm.
Having an RDT test reduced the chance of purchasing
an anti-malarial by 42% (95% CI: 38%-46%) compared to
not having a test. Figure 2 shows the daily anti-malarialTable 3 Multivariate analysis examining risk factors for
RDT confirmed malaria
Risk factors for malaria Odds ratio Adjusted odds
ratio
(95% CI) (95% CI)
P value P value
Adult age group 0.384 (0.214-0.688) 0.514 (0.280-0.946)
0.001 0.033
Reported positive lab test
prior to presentation
2.221 (1.282-3.812) 2.177 (1.208-3.925)
0.004 0.010
A history of fever in the
last 48 hours
4.441 (2.757-7.151) 4.027 (2.482-6.532)
< 0.001 < 0.001
Reported last treatment
for malaria (more than
6 months ago)
1.611 (1.014-2.560) 1.627 (1.002-2.640)
0.042 0.049sales for each pharmacy before and during the study.
51.6% (276) of the study participants with an RDT nega-
tive result still purchased anti-malarials. Patients were
more inclined to purchase an anti-malarial, even though
RDT result was negative, if it had been recommended by
a health professional (58.9%) compared to self-referral
(44.2%) (P = 0.001). Patients with RDT negative results
were also more likely to purchase an anti-malarial if
there was a reported malaria positive lab test prior to
presentation (66.2%; P = 0.007), a history of fever in the
last 48 hours (60.5%; P = 0.027), and primary school edu-
cation or less (69.4%; P = 0.009).
A multivariate analysis (Table 4), showed that after
adjusting for age group and gender differences, having at
least a secondary school education reduced the chance of
buying an anti-malarial (OR 0.504 (95% CI: 0.256-0.993))
compared to having primary education or lower. Having
an anti-malarial recommended to the patient by a health
professional and reporting a previous positive lab result
prior to presentation significantly increased the chance of
an anti-malarial sale. The prescription rates of different
anti-malarial drugs and their disposition within both study
arms and sub-groups in the intervention pharmacy are
provided in Figure 3 and Table 5.
Discussion
This study is the first of its kind in West Africa, and
only the second study in Africa, that attempts to show
the effect of RDTs on anti-malarial sales in pharmacies
and it highlighted a number of interesting findings. An
overall incidence of 13.6% was slightly lower than ex-
pected, considering that the study was conducted at a
time when the study area was considered holo-endemic
for malaria [18]; however it now is regarded as meso-
endemic in an unpublished report by the NMCP [19].
The result is in line with other studies that demonstrateFigure 2 A box plot showing the total mean daily number of
anti-malarial sales in the intervention and control pharmacy
35 days prior to the start of the study (Retrospective) and
35 days after the study commenced (Prospective).
Table 4 Selected risk factors for anti-malarial purchase
after an RDT negative test result showing adjusted
and unadjusted odds
Risk factors for
anti-malarial sale
Odds ratio
intervention
(RDT negatives only)
(95% CI) P value
Adjusted odds ratio
(RDT negatives only)
(95% CI) P value
Average income
or more
0.658 (0.465-0.931) 0.687 (0.468-1.007)
0.018 0.054
At least secondary
education
0.438 (0.232-0.824) 0.504 (0.256-0.993)
0.009 0.048
Reported positive
lab test prior to
presentation
2.020 (1.207-3.382) 1.737 (1.007-2.996)
0.007 0.047
Reported last treatment
for malaria (more than
6 months ago)
0.782 (0.549-1.114) 0.714 (0.494-1.032)
0.173 0.073
Anti-malarial
recommended by a
health professional
1.812 (1.286-2.553) 1.617 (1.134-2.305)
0.001 0.008
A history of fever in
the last 48 hours
1.592 (1.051-2.410) 1.440 (0.934-2.218)
0.027 0.098
Table 5 Anti-malarial prescription practice in both study
arms showing the frequency of use of different ACT and
non-ACT drugs within each study group
Antimalarial dispensed Intervention
pharmacy
(frequency and %
antimalarials
within study arm)
n = 360
Control pharmacy
(frequency and %
antimalarials
within study arm)
n = 607
Artemether-Lumefantrine 180 337
(50.0%) (55.5%)
Artesunate-Amodiaquine 42 47
(11.7%) (7.7%)
Dihydroartemisinin-
Piperaquine
30 33
(8.3%) (5.4%)
Artesunate-Sulfadoxine-
Pyrimethamine
8 12
(2.2%) (2.0%)
ACT (total) 260 429
(72.2%) (70.6%)
Sulfadoxine-
Pyrimethamine alone
39 75
(10.8%) (12.4%)
Artesunate alone 47 58
(13.1%) (9.6%)
Chloroquine alone 13 30
(3.6%) (4.9%)
Quinine alone 1 15
(0.3%) (2.5%)
Non-ACT (total) 100 178
(27.8%) (29.4%)
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The incidence in adolescents was higher (26.0%) com-
pared to the adult age group (11.0%), especially if they
had a history of fever in the last 48 hours (47.1%). Epide-
miologically, adolescents and adults tend to be classified
together on the basis of incidence and clinical presenta-
tion of malaria even though it is well documented that
the incidence of malaria reduces progressively with in-
creasing age after the age of five [23]. The results again
highlight the need to better understand the dynamics of
malaria in this age group.
Studies have suggested the introduction of RDTs to
pharmacies in recognition of its importance in theFigure 3 Schematic summary of the number and disposition of
anti-malarials within different sub-groups in the intervention
pharmacy.treatment of malaria in most African settings [24], but
only one previous African study has demonstrated its ef-
fect on anti-malarial prescription [25]. This study clearly
shows that having an RDT before treatment reduces the
chance of selling anti-malarials to adolescents or non-
pregnant adults with symptoms of uncomplicated mal-
aria in a community pharmacy by 42%. The estimated
reduction from this study is considerably less than that
reported by other studies, which showed a 77% [26] and
96% [27] reduction in anti-malarial prescriptions with
RDT use. However, there are good reasons for this dif-
ference. Firstly, unlike these studies, this study did not
interfere with the decision of pharmacists or patients to
treat malaria, irrespective of the outcome of the result,
as this is likely to be the case in most pharmacies in
Nigeria. Secondly, as opposed to government owned pub-
lic health facilities, pharmacies are primarily established
for profit. Therefore, it may prove extremely difficult to
persuade pharmacies to restrict the sale of anti-malarials
to only RDT positive patients, unless alternative sources
of income are made available. Zikusooka et al. [28]
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RDT positive patients will save up to $2.12 per person,
assuming that RDT and ACT were sold at government
approved prices of $0.95 and $2.40 respectively, when 25%
or less of the population test positive for malaria. Bearing
in mind the current cost of ACT in the free market (ACT
accounted for 72.2% of anti-malarial prescriptions in the
intervention study arm), a 42% reduction in anti-malarial
sales would lead to considerable economic benefit if the
overall incidence is 13.6%.
Prior to the start of this study, the study nurse, pharma-
cists and staff of the intervention pharmacy were trained
on how to use RDTs. Most RDT tests were conducted by
the study nurse, who was provided by the study team on
the request of the intervention pharmacy, to reduce the
workload on the pharmacists and other staff. This is rep-
resentative of most pharmacies and drugs shops in Nigeria
who employ nurses or Community Health Extension
Workers, to assess patients, administer intravenous medi-
cations and give basic first aid treatment when required.
Substantial interest in the value of RDTs as a tool for
proper case detection and management of malaria by
trained health care personnel in the public health sector
is well documented [29]. This study suggests that there
should be more effort at extending proper case detection
and management to pharmacies and other private health
sector facilities, leveraging on already existing health
care workers, with particular benefits in adults and ado-
lescents seeking to buy anti-malarials without a reported
history of fever in the last 48 hours.
In this study, only a previous reported positive labo-
ratory result, greater than secondary education and
recommendation of an anti-malarial by a health profes-
sional were found to significantly affect the sale of anti-
malarials when the RDT result is negative. There is a
wealth of evidence that better education is associated
with improved health and better health seeking beha-
viour and the findings from this study are in line with
this. It is understandable why anti-malarial recommen-
dations from a health professional would significantly in-
crease anti-malarial use even if the RDT was negative
and this highlights the importance of educating health
professionals to use appropriate diagnostic tests. Posses-
sing a positive laboratory test (usually microscopy) prior
to presentation also significantly increased the sale of
anti-malarials to RDT negative patients. This is not con-
sistent with findings from another study in Zambia,
which suggests that anti-malarials are less likely to be
prescribed if RDTs are used rather than microscopy [30].
The Zambian study was performed in a hospital with
trained health professionals that had little faith in their
microscopy results. Since RDT was a new intervention
in that study and it seem to work, the clinicians were
more inclined to adhere to the RDT results compared tomicroscopy. In this study, both pharmacists and patients
were more inclined to believe the results of the labora-
tory test, as it was considered to be superior to the
RDTs. However, considering that only 22.9% of partici-
pants with a reported positive laboratory test just prior
to presentation tested positive for malaria, and in view
of the quality assured RDT results, it is fair to say that
the quality of routine microscopy in this setting is poor.
Education campaigns aimed at pharmacists and patients
might help to publicize the advantages of RDT use be-
fore anti-malarial prescription in this setting.
There are a number of limitations to this study; it in-
volved only two sites and the presence of the investiga-
tor may have altered the behaviour of both pharmacist
and patients- towards the end of the study, there was
some evidence that the pharmacist in the intervention
pharmacy was becoming concerned about loss of sales.
Nevertheless, the magnitude of the change in anti-
malarial prescription when using RDTs compared to the
control pharmacy is considerable.
The authors believe that the pharmacies used are rep-
resentative of registered community pharmacies in the
study area because the pre-study assessment of re-
gistered pharmacies showed similarities in their daily
average anti-malarial prescription rates and practices;
including prescribing anti-malarials without a doctor’s
prescription. In addition, there was no observed dispa-
rity in social class or educational status among patients
patronizing the pharmacies. Furthermore, prices of drugs
in community pharmacies are regulated by the Asso-
ciation of Community Pharmacies of Nigeria (ACPN),
hence, prices and availability of anti-malarials were ob-
served to be similar. However, because the study area is in
the Federal Capital Territory of Nigeria, which hosts the
ACPN, it is plausible that unregistered community phar-
macies exist in the area. The study highlights the enor-
mous potential for improving appropriate prescription
of anti-malarials in pharmacies and preventing unneces-
sary ACT use. Further research on replicating the fin-
dings in other settings, and exploring how pharmacists
could be incentivized to use this approach is urgently
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